U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ACHIRAL
Molecular Formula C4H7NO2S
Molecular Weight 133.169
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DAPANSUTRILE

SMILES

CS(=O)(=O)CCC#N

InChI

InChIKey=LQFRYKBDZNPJSW-UHFFFAOYSA-N
InChI=1S/C4H7NO2S/c1-8(6,7)4-2-3-5/h2,4H2,1H3

HIDE SMILES / InChI

Description

Dapansutrile is an inhibitor of the NLRP3 inflammasome, developed by Olatec Therapeutics LLC. NLRP3 inflammasome is a driver of sterile inflammation in response to myocardial ischemia-reperfusion and other inflammatory conditions. Dapansutrile limits infarct size and prevents left ventricular systolic dysfunction in the mouse model of ischemia-reperfusion injury and suppresses joint inflammation in the mouse model of acute arthritis. Dapansutrile demonstrated a clinical and inflammatory cytokine response in a clinical trial for the treatment of acute gout and is being investigated for the treatment of Systolic Heart Failure and Schnitzler Syndrome.

Approval Year

Unknown
149,124

Targets

Primary TargetPharmacologyConditionPotency
Interleukin-1 beta
22
Modulator
846
inflammasome complex
2
Inhibitor
8,504

Cmax

ValueDoseCo-administeredAnalytePopulation
2700 ng/mL
100 mg single, oral
 DAPANSUTRILE plasma
Homo sapiens
9800 ng/mL
300 mg single, oral
 DAPANSUTRILE plasma
Homo sapiens
32000 ng/mL
1000 mg single, oral
 DAPANSUTRILE plasma
Homo sapiens
4800 ng/mL
100 mg 1 times / day multiple, oral
 DAPANSUTRILE plasma
Homo sapiens
15800 ng/mL
300 mg 1 times / day multiple, oral
 DAPANSUTRILE plasma
Homo sapiens
41400 ng/mL
1000 mg 1 times / day multiple, oral
 DAPANSUTRILE plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
40121.19 ng × h/mL
100 mg single, oral
 DAPANSUTRILE plasma
Homo sapiens
157378.19 ng × h/mL
300 mg single, oral
 DAPANSUTRILE plasma
Homo sapiens
464809.56 ng × h/mL
1000 mg single, oral
 DAPANSUTRILE plasma
Homo sapiens
70288.75 ng × h/mL
100 mg 1 times / day multiple, oral
 DAPANSUTRILE plasma
Homo sapiens
260409.24 ng × h/mL
300 mg 1 times / day multiple, oral
 DAPANSUTRILE plasma
Homo sapiens
723127.43 ng × h/mL
1000 mg 1 times / day multiple, oral
 DAPANSUTRILE plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
23.01 h
100 mg single, oral
 DAPANSUTRILE plasma
Homo sapiens
22.8 h
300 mg single, oral
 DAPANSUTRILE plasma
Homo sapiens
24.15 h
1000 mg single, oral
 DAPANSUTRILE plasma
Homo sapiens
16.01 h
100 mg 1 times / day multiple, oral
 DAPANSUTRILE plasma
Homo sapiens
21.34 h
300 mg 1 times / day multiple, oral
 DAPANSUTRILE plasma
Homo sapiens
24.72 h
1000 mg 1 times / day multiple, oral
 DAPANSUTRILE plasma
Homo sapiens
ACTIVE MOIETY
Structure of DAPANSUTRILE
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966